TY - JOUR
T1 - Incorporation and metabolism of exogenous G(M1) ganglioside in rat liver
AU - Ghidoni, R.
AU - Trinchera, M.
AU - Venerando, B.
AU - Fiorilli, A.
AU - Sonnino, S.
AU - Tettamanti, G.
PY - 1986
Y1 - 1986
N2 - The pathways of metabolic processing of exogenously administered G(M1) ganglioside in rat liver was investigated at the subcellular level. The G(M1) used was 3H-labelled at the level of long-chain base ([Sph(sphingosine)-3H]G(M1)) or of terminal galactose ([Gal-3H)G(M1)). The following radioactive compounds, derived from exogenous G(M1), were isolated and chemically characterized: gangliosides G(M2), G(M3), G(D1a) and G(D1b) {nomenclature of Svennerholm [(1964) J. Lipid Res. 5, 145-155] and IUPAC-IUB Recommendations [(1977) Lipids 12, 455-468]}; lactosylceramide, glucosylceramide and ceramide; sphingomyelin. G(M2), G(M3), lactosylceramide, glucosylceramide and ceramide, relatively more abundant shortly after G(M1) administration, were mainly present in the lysosomal fraction and reflected the occurrence of a degradation process. 3H2O was also produced in relevant amounts, indicating complete degradation of G(M1), although no free long-chain bases could be detected. G(D1a) and G(D1b), relatively more abundant later on later administration, were preponderant in the Golgi-apparatus fraction and originated from a biosynthetic process. More G(D1a) was produced starting from [Sph-3H]G(M1) than from [Gal-3]G(M1), and radioactive G(D1b) was present only after [Sph-3H]G(M1) injection. This indicates the use of two biosynthesis routes, one starting from a by-product of G(M1) degradation, the other implicating direct sialylation of G(M1). Both routes were used to produce G(D1a), but only the first one for producing G(D1b). Sphingomyelin was the major product of G(M1) processing, especially at the longer times after injection, and arose from a by-product of G(M1) degradation, most likely ceramide.
AB - The pathways of metabolic processing of exogenously administered G(M1) ganglioside in rat liver was investigated at the subcellular level. The G(M1) used was 3H-labelled at the level of long-chain base ([Sph(sphingosine)-3H]G(M1)) or of terminal galactose ([Gal-3H)G(M1)). The following radioactive compounds, derived from exogenous G(M1), were isolated and chemically characterized: gangliosides G(M2), G(M3), G(D1a) and G(D1b) {nomenclature of Svennerholm [(1964) J. Lipid Res. 5, 145-155] and IUPAC-IUB Recommendations [(1977) Lipids 12, 455-468]}; lactosylceramide, glucosylceramide and ceramide; sphingomyelin. G(M2), G(M3), lactosylceramide, glucosylceramide and ceramide, relatively more abundant shortly after G(M1) administration, were mainly present in the lysosomal fraction and reflected the occurrence of a degradation process. 3H2O was also produced in relevant amounts, indicating complete degradation of G(M1), although no free long-chain bases could be detected. G(D1a) and G(D1b), relatively more abundant later on later administration, were preponderant in the Golgi-apparatus fraction and originated from a biosynthetic process. More G(D1a) was produced starting from [Sph-3H]G(M1) than from [Gal-3]G(M1), and radioactive G(D1b) was present only after [Sph-3H]G(M1) injection. This indicates the use of two biosynthesis routes, one starting from a by-product of G(M1) degradation, the other implicating direct sialylation of G(M1). Both routes were used to produce G(D1a), but only the first one for producing G(D1b). Sphingomyelin was the major product of G(M1) processing, especially at the longer times after injection, and arose from a by-product of G(M1) degradation, most likely ceramide.
UR - http://www.scopus.com/inward/record.url?scp=0022496404&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022496404&partnerID=8YFLogxK
M3 - Article
C2 - 3800874
AN - SCOPUS:0022496404
VL - 237
SP - 147
EP - 155
JO - Biochemical Journal
JF - Biochemical Journal
SN - 0264-6021
IS - 1
ER -